How does John Kane, MD, address issues of cognition in schizophrenia?
John M. Kane, MD
Advertisement
Articles by John M. Kane, MD
John Kane, MD, believes the removal of the REMS requirement for clozapine could help improve utilization for this "grossly underutilized" drug.
John Kane, MD, shares why you should be paying attention to LB-102 for the treatment of schizophrenia.
In this exclusive interview with Psychiatric Times, John Kane, MD, shares more on the new positive data on LB-102 for the treatment of acutely exacerbated schizophrenia.
A comprehensive discussion on new treatment options for patients with schizophrenia, highlighting the potential for earlier intervention to optimize treatment outcomes.
Compliance is a major issue in treatment of schizophrenia. How can compliance be improved, and can newer formulations make that compliance easier?
Advertisement
Latest Updated Articles
- Reducing Nonadherence: New Formulations of Antipsychotic Medications
Published: February 1st 2006 | Updated:
Advertisement
Advertisement
Trending on Psychiatric Times
1
Increased Risk of Death in Patients With Dementia Found Related to Common Hospice Medications
2
How to Approach Conversations With Adult Patients Who Might Have ADHD: New Tools and Insights
3
FDA Approves Uzedy Once-Monthly Extended Release Injectable Suspension for Bipolar I Disorder
4
The Use of Aripiprazole for Bipolar Disorder
5
